Ming-Horng Tsai1, Jen-Fu Hsu, Shih-Ming Chu, Reyin Lien, Hsuan-Rong Huang, Ming-Chou Chiang, Ren-Huei Fu, Chiang-Wen Lee, Yhu-Chering Huang. 1. From the *Department of Pediatrics, Division of Neonatology and Pediatric Hematology/Oncology, Chang Gung Memorial Hospital, Yunlin; †College of Medicine, Chang Gung University, Taoyuan; ‡Chang Gung University of Science and Technology, Chiayi; §Department of Pediatrics, Division of Pediatric Neonatology; and ¶Department of Pediatrics, Division of Pediatric Infectious Disease, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Abstract
BACKGROUND: Late-onset sepsis (LOS) is a common complication in the neonatal intensive care unit. We aimed to describe the epidemiology, clinical characteristics and risk factors for adverse outcome in neonates with LOS. METHODS: We conducted a cohort study of all neonates with LOS at the neonatal intensive care unit of a Tertiary Taiwan Medical Center from January 2004 through December 2011 and used multivariate logistic regression to identify risk factors for final adverse outcome. RESULTS: Among 5010 neonates over 253,644 neonate-days, 713 (14.2%) experienced a total of 942 episodes of LOS (incidence rate, 3.71 episodes per 1000 neonate-days). Although the rates of LOS were inversely proportional to birth weight and gestational age, the incidence rates were comparable among extremely preterm, late preterm and full term neonates. Fungemia was found to have significantly higher rate of infectious complication (30.8%), persistent bloodstream infection (19.2%) and sepsis attributable mortality (23.1%). The overall mortality rate was 12.6% (90/713), and sepsis attributable mortality rate was 7.2% (68/942 episodes). Independent predictors of in-hospital mortality were Pseudomonas LOS (adjusted odds ratio [OR], 14.31; 95% confidence interval [CI]: 3.87-53.0), fungemia (OR, 5.69; 95% CI: 2.48-13.01), presence of congenital anomalies (OR, 4.12; 95% CI: 1.60-10.60), neuromuscular comorbidities (OR, 3.34; 95% CI: 1.66-6.73) and secondary pulmonary hypertension with/without cor pulmonale (OR, 23.48; 95% CI: 5.96-92.49). CONCLUSIONS: LOS predisposes hospitalized neonates to increased risk of mortality or morbidity, especially caused by Pseudomonas aeruginosa or Candida spp. More aggressive treatment strategy is worth consideration in neonates with presumed LOS, particularly those with certain underlying chronic conditions.
BACKGROUND: Late-onset sepsis (LOS) is a common complication in the neonatal intensive care unit. We aimed to describe the epidemiology, clinical characteristics and risk factors for adverse outcome in neonates with LOS. METHODS: We conducted a cohort study of all neonates with LOS at the neonatal intensive care unit of a Tertiary Taiwan Medical Center from January 2004 through December 2011 and used multivariate logistic regression to identify risk factors for final adverse outcome. RESULTS: Among 5010 neonates over 253,644 neonate-days, 713 (14.2%) experienced a total of 942 episodes of LOS (incidence rate, 3.71 episodes per 1000 neonate-days). Although the rates of LOS were inversely proportional to birth weight and gestational age, the incidence rates were comparable among extremely preterm, late preterm and full term neonates. Fungemia was found to have significantly higher rate of infectious complication (30.8%), persistent bloodstream infection (19.2%) and sepsis attributable mortality (23.1%). The overall mortality rate was 12.6% (90/713), and sepsis attributable mortality rate was 7.2% (68/942 episodes). Independent predictors of in-hospital mortality were Pseudomonas LOS (adjusted odds ratio [OR], 14.31; 95% confidence interval [CI]: 3.87-53.0), fungemia (OR, 5.69; 95% CI: 2.48-13.01), presence of congenital anomalies (OR, 4.12; 95% CI: 1.60-10.60), neuromuscular comorbidities (OR, 3.34; 95% CI: 1.66-6.73) and secondary pulmonary hypertension with/without cor pulmonale (OR, 23.48; 95% CI: 5.96-92.49). CONCLUSIONS: LOS predisposes hospitalized neonates to increased risk of mortality or morbidity, especially caused by Pseudomonas aeruginosa or Candida spp. More aggressive treatment strategy is worth consideration in neonates with presumed LOS, particularly those with certain underlying chronic conditions.
Authors: Sofia El Manouni El Hassani; Daniel J C Berkhout; Hendrik J Niemarkt; Sarah Mann; Willem P de Boode; Veerle Cossey; Christian V Hulzebos; Anton H van Kaam; Boris W Kramer; Richard A van Lingen; Johannes B van Goudoever; Daniel C Vijlbrief; Mirjam M van Weissenbruch; Marc A Benninga; Nanne K H de Boer; Tim G J de Meij Journal: Neonatology Date: 2019-04-04 Impact factor: 4.035
Authors: Matthew McGovern; Eric Giannoni; Helmut Kuester; Mark A Turner; Agnes van den Hoogen; Joseph M Bliss; Joyce M Koenig; Fleur M Keij; Jan Mazela; Rebecca Finnegan; Marina Degtyareva; Sinno H P Simons; Willem P de Boode; Tobias Strunk; Irwin K M Reiss; James L Wynn; Eleanor J Molloy Journal: Pediatr Res Date: 2020-03-03 Impact factor: 3.756
Authors: Grace Li; Joseph F Standing; Julia Bielicki; William Hope; John van den Anker; Paul T Heath; Mike Sharland Journal: Drugs Date: 2017-06 Impact factor: 9.546
Authors: Christopher M Pruitt; Mark I Neuman; Samir S Shah; Veronika Shabanova; Christopher Woll; Marie E Wang; Elizabeth R Alpern; Derek J Williams; Laura Sartori; Sanyukta Desai; Rianna C Leazer; Richard D Marble; Russell J McCulloh; Adrienne G DePorre; Sahar N Rooholamini; Catherine E Lumb; Fran Balamuth; Sarah Shin; Paul L Aronson Journal: J Pediatr Date: 2018-10-05 Impact factor: 4.406
Authors: Daniel S Tawfik; Jochen Profit; Eileen T Lake; Jessica B Liu; Lee M Sanders; Ciaran S Phibbs Journal: Health Serv Res Date: 2019-12-23 Impact factor: 3.402